Tempus AI, Inc.

Tempus AI, Inc. (Nasdaq: TEM) operates as a healthcare technology company focused on unlocking the power of precision medicine through artificial intelligence-enabled diagnostics. The company's website is www.tempus.com.

Tempus has developed the Tempus Platform, a vertically integrated infrastructure that combines proprietary software, dedicated data pipelines, and a multimodal database to enable what the company calls Intelligent Diagnostics. These diagnostics contextualize laboratory test results with a patient's unique clinical data, molecular information, and outcomes from similarly situated patients to personalize therapy selection and treatment decisions. The platform connects multiple stakeholders across the healthcare ecosystem through approximately 700 direct data connections spanning more than 5,000 healthcare institution sites, reaching over 55 percent of U.S. oncologists.

The company operates two primary product lines. The Diagnostics segment provides comprehensive laboratory testing services through five high-throughput laboratories offering next-generation sequencing, PCR profiling, and anatomic and molecular pathology tests, with particular focus on oncology and hereditary cancer screening. The Data and applications segment monetizes de-identified patient data and provides analytics, clinical trial matching, and algorithmic diagnostic products to pharmaceutical, biotechnology, and research organizations.

Tempus has assembled one of the largest libraries of clinical and molecular oncology data globally, comprising approximately 1.4 billion documents across more than 8.6 million de-identified patient records, including over 1.6 billion pages of clinical text, 8 million records with imaging data, and 1.5 million records with matched genomic information. The company's database spans multiple disease areas including oncology, neurology, and cardiology, with expanding capabilities following the February 2025 acquisition of Ambry Genetics Corporation and the November 2025 acquisition of OneOme, Inc.

The company's business model creates network effects whereby increased diagnostic testing volume generates more data, which improves test accuracy and enables new applications, attracting more physicians and researchers to the platform. This flywheel effect strengthens Tempus's competitive position as a healthcare AI company straddling both clinical care delivery and technology innovation.